PSEN1 and Alzheimer disease: In vivo administration of 3a in APP/PS1 mice, a double-transgenic mouse expressing a chimeric mouse/human amyloid precursor protein and a mutant human presenilin 1 (animal model of AD), led to an improvement of neuronal survival and decreased microglial cell density and plaque load [21].